Patent Grant
9782589
Some applications of the invention relate in general to implantable electrostimulators. More specifically, some applications of the present invention relate to improving blood flow using implantable electrostimulators.
Peripheral artery occlusive disease (PAOD) (also known as peripheral artery disease, peripheral vascular disease, and peripheral obliterative arteriopathy) is a condition in which peripheral arteries (i.e., arteries except those that supply the heart or the brain) are narrowed. PAOD is associated with diabetes, smoking, hypertension, and hypercholesterolemia, and is often the result of atherosclerosis. PAOD affects over 200 million people worldwide.
An electrostimulator implant is implanted in a subject that has, or is at risk of developing, peripheral artery occlusive disease (PAOD). For some applications, the implant comprises a detector that detects a factor indicative of local blood supply in the tissue of a limb in which the implant is implanted. For some applications, an extracorporeal device is attached to the limb, and provides wireless power, processing power, and/or additional sensors.
There is therefore provided, in accordance with an application of the present invention, apparatus, including:
In an application, the intracorporeal sensor includes a temperature sensor, configured to detect a temperature of the tissue.
In an application, the intracorporeal sensor includes an oximeter, configured to detect an oxygen saturation of the tissue.
In an application, the intracorporeal sensor includes a pressure sensor, configured to detect a pressure within the tissue.
In an application, the intracorporeal sensor includes an accelerometer, configured to detect movement indicative of expansion of an artery of the limb.
In an application, the bloodflow-increasing current has a frequency of 1-100 Hz, and the circuitry is configured to drive the electrode to apply the 1-100 Hz bloodflow-increasing current to the tissue at least in part responsively to the detected movement.
In an application, the apparatus further includes an extracorporeal device, attachable to the limb, and configured:
In an application, the extracorporeal device includes an extracorporeal sensor, configured to detect a factor indicative of local blood supply in the tissue of the limb, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the factor detected by the intracorporeal sensor, and (ii) the factor detected by the extracorporeal sensor.
In an application, the extracorporeal sensor includes a temperature sensor, configured to detect a temperature of the tissue.
In an application, the extracorporeal sensor includes an oximeter, configured to detect an oxygen saturation of the limb.
In an application, the extracorporeal sensor includes a pressure sensor, configured to detect a pressure within the limb.
In an application, the extracorporeal sensor includes an accelerometer, configured to detect movement indicative of expansion of an artery of the limb.
In an application, the extracorporeal device includes an extracorporeal accelerometer, configured to detect movement of the limb, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the factor detected by the intracorporeal sensor, and (ii) the movement detected by the extracorporeal accelerometer.
In an application, the extracorporeal device includes an extracorporeal temperature sensor, configured to detect an ambient temperature, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the factor detected by the intracorporeal sensor, and (ii) the ambient temperature detected by the extracorporeal temperature sensor.
In an application, the extracorporeal device is configured to alternate between (i) a first mode in which the extracorporeal device wirelessly drives the circuitry to drive the electrode to apply the bloodflow-increasing current, the bloodflow-increasing current having a frequency of 1-100 Hz, and (ii) a second mode in which the extracorporeal device wirelessly drives the circuitry to apply a second electrical current having a frequency of 1-10 kHz.
There is further provided, in accordance with an application of the present invention, apparatus, including:
In an application, the bloodflow-increasing current has a frequency of 1-100 Hz, and the circuitry is configured to drive the electrode to apply the 1-100 Hz bloodflow-increasing current to the tissue at least in part responsively to the detected temperature.
In an application, the circuitry is configured to drive the electrode to apply the bloodflow-increasing current in response to the detected temperature being below a threshold temperature.
In an application, the apparatus further includes an extracorporeal device, attachable to the limb, and configured to wirelessly transmit the power received by the antenna.
In an application, the extracorporeal device is configured:
In an application, the temperature sensor is a first temperature sensor, the extracorporeal device includes a second temperature sensor, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the temperature detected by the first temperature sensor, and (ii) a temperature detected by the second temperature sensor.
In an application, the extracorporeal device is configured to alternate between (i) a first mode in which the extracorporeal device wirelessly drives the circuitry to drive the electrode to apply a first electrical current having a frequency of 1-100 Hz, and (ii) a second mode in which the extracorporeal device wirelessly drives the circuitry to apply a second electrical current having a frequency of 1-10 kHz.
In an application, the implant further includes a pressure sensor, configured to detect a pressure within the tissue, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pressure.
In an application, the pressure includes a pulse pressure, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pulse pressure.
There is further provided, in accordance with an application of the present invention, apparatus, including:
In an application, the circuitry is configured to drive the electrode to apply the bloodflow-increasing current in response to the detected oxygen saturation being below a threshold oxygen saturation.
In an application, the bloodflow-increasing current has a frequency of 1-100 Hz, and the circuitry is configured to drive the electrode to apply the 1-100 Hz bloodflow-increasing current to the tissue at least in part responsively to the detected oxygen saturation.
In an application, the apparatus further includes an extracorporeal device, attachable to the limb, and configured to wirelessly transmit the power received by the antenna.
In an application, the extracorporeal device is configured:
In an application, the oximeter is a first oximeter, the extracorporeal device includes a second oximeter, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the oxygen saturation detected by the first oximeter, and (ii) an oxygen saturation detected by the second oximeter.
In an application, the extracorporeal device is configured to alternate between (i) a first mode in which the extracorporeal device wirelessly drives the circuitry to drive the electrode to apply a first electrical current having a frequency of 1-100 Hz, and (ii) a second mode in which the extracorporeal device wirelessly drives the circuitry to apply a second electrical current having a frequency of 1-10 kHz.
In an application, the implant further includes a pressure sensor, configured to detect a pressure within the tissue, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pressure.
In an application, the detected pressure includes a pulse pressure, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pulse pressure.
There is further provided, in accordance with an application of the present invention, apparatus, including:
In an application, the detected pressure includes a pulse pressure, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pulse pressure.
In an application, the bloodflow-increasing current has a frequency of 1-100 Hz, and the circuitry is configured to drive the electrode to apply the 1-100 Hz bloodflow-increasing current to the tissue at least in part responsively to the detected pressure.
In an application, the apparatus further includes an extracorporeal device, attachable to the limb, and configured to wirelessly transmit the power received by the antenna.
In an application, the extracorporeal device is configured:
In an application, the pressure sensor is a first pressure sensor, the extracorporeal device includes a second pressure sensor, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the pressure detected by the first pressure sensor, and (ii) a pressure detected by the second pressure sensor.
In an application, the extracorporeal device is configured to alternate between (i) a first mode in which the extracorporeal device wirelessly drives the circuitry to drive the electrode to apply a first electrical current having a frequency of 1-100 Hz, and (ii) a second mode in which the extracorporeal device wirelessly drives the circuitry to apply a second electrical current having a frequency of 1-10 kHz.
There is further provided, in accordance with an application of the present invention, apparatus, including:
In an application, the circuitry is configured to drive the electrode to apply the bloodflow-increasing current in response to a magnitude of the detected movement being below a threshold magnitude.
In an application, the bloodflow-increasing current has a frequency of 1-100 Hz, and the circuitry is configured to drive the electrode to apply the 1-100 Hz bloodflow-increasing current to the tissue at least in part responsively to the detected movement.
In an application, the apparatus further includes an extracorporeal device, attachable to the limb, and configured to wirelessly transmit the power received by the antenna.
In an application, the extracorporeal device is configured:
In an application, the accelerometer is a first accelerometer, the extracorporeal device includes a second accelerometer, and the extracorporeal device is configured to wirelessly drive the circuitry to drive the electrode to apply the bloodflow-increasing current to the tissue, at least in part responsively to (i) the movement detected by the first accelerometer, and (ii) a movement detected by the second accelerometer.
In an application, the extracorporeal device is configured to alternate between (i) a first mode in which the extracorporeal device wirelessly drives the circuitry to drive the electrode to apply a first electrical current having a frequency of 1-100 Hz, and (ii) a second mode in which the extracorporeal device wirelessly drives the circuitry to apply a second electrical current having a frequency of 1-10 kHz.
In an application, the implant further includes a pressure sensor, configured to detect a pressure within the tissue, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pressure.
In an application, the detected pressure includes a pulse pressure, and the circuitry is configured to drive the electrode to apply the current at least in part responsively to the detected pulse pressure.
There is further provided, in accordance with an application of the present invention, a method of treating a subject, the method including:
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a blood-flow change induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to a blood-flow change induced by the activating of the implant.
In an application, identifying the subject includes identifying the subject as not suffering from peripheral polyneuropathy.
In an application, activating the implant includes activating the implant without inducing paresthesia.
In an application, activating the implant includes activating the implant such that it applies to the limb an electrical current having a frequency of 1-100 Hz.
In an application, activating the implant includes activating the implant to alternate between a first mode in which the implant applies a first electrical current having a frequency of 1-100 Hz, and a second mode in which the implant applies a second electrical current having a frequency of 1-10 kHz.
In an application, activating the implant includes activating the implant such that (i) the implant increases the blood flow in the limb by applying the first electrical current to the limb, and (ii) the implant induces relieves pain by applying the second electrical current to the limb.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a blood-flow change induced by the activating of the implant.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a level of pain relief induced by the activating of the implant.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a level of paresthesia induced by the activating of the implant.
In an application, the method further includes:
In an application, the method further includes:
In an application, the method further includes calibrating the implant at least in part responsively to a blood-flow change induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to a level of pain relief induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to a level of paresthesia induced by the activating of the implant.
In an application, the method further includes:
In an application, the method further includes:
In an application, activating the implant includes activating the implant to alternate between being in the first mode for 1-30 minutes, and being in the second mode for 1-10 minutes.
In an application, the step of identifying includes (i) receiving infrared emission information, and (ii) identifying the subject as having PAOD at least in part responsively to the infrared emission information.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to an infrared-emission change induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to an infrared-emission change induced by the activating of the implant.
In an application, receiving the infrared emission information includes receiving a thermographic image of the subject.
In an application, the step of identifying includes (i) receiving temperature information, and (ii) identifying the subject as having PAOD at least in part responsively to the temperature information.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a temperature change induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to a temperature change induced by the activating of the implant.
In an application, the step of identifying includes (i) receiving Doppler information, and (ii) identifying the subject as having PAOD at least in part responsively to the Doppler information.
In an application, the method further includes repositioning the implant within the limb at least in part responsively to a Doppler change induced by the activating of the implant.
In an application, the method further includes calibrating the implant at least in part responsively to a Doppler change induced by the activating of the implant.
In an application, implanting the electrostimulator in the limb includes implanting the electrostimulator in a leg of the subject.
In an application, implanting the electrostimulator in the leg includes implanting the electrostimulator within 10 mm of a tibial nerve of the subject.
In an application, activating the implant includes activating the implant such that it applies an electrical current to the tibial nerve.
There is further provided, in accordance with an application of the present invention, apparatus for treating a subject, the apparatus including:
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Reference is made to
Implant 22 comprises one or more tissue-contacting electrodes 24 disposed at an outer surface of the implant, and circuitry 26 configured to drive the electrodes to apply a treatment current to tissue that is in contact with the electrodes (e.g., circuitry 26 defines and/or comprises a control unit 28). Implant 22 comprises a battery 30, or an antenna 32, or both. For some applications, implant 22 comprises a power source, such as a primary battery, and does not comprise an antenna. For some applications, antenna 32 is configured to receive wireless power. For some such applications, the received wireless power is used by circuitry 26 to recharge battery 30. For some such applications, the received wireless power is used by circuitry 26 to immediately (e.g., within 1 second of receiving the wireless power) drive electrodes 24 to apply the treatment current. For example, implant 22 may not comprise battery 30 or another non-transient power source (although the implant may comprise a capacitor).
Introducer 40 comprises a tube 42 that defines a lumen and is percutaneously-advanceable into a subject. The lumen of tube 42 is dimensioned to house implant 22 at least temporarily. Introducer 40 is configured to deploy the implant from a distal end of the lumen by moving the implant and the distal end of the lumen relative to each other. For example, once implant 22 is disposed inside the subject, within a distal portion of the introducer, tube 42 may be withdrawn proximally while a reference-force rod 44, reversibly coupled to the implant, and slidable with respect to tube 42, holds the implant stationary by providing a reference force to the implant. Alternatively, rod 44 may push implant 22 out of the distal end of tube 42 while the tube is maintained stationary.
Typically, implant 22 has a transverse cross-sectional area (i.e., transverse to the longitudinal axis of the implant along which the implant is injected) of 0.5-8 mm^2 (e.g., 1-4 mm^2).
Reference is made to
Typically, the subject has been previously diagnosed with PAOD (e.g., independently and/or elsewhere), and step 62 is performed by inspecting the medical records of the subject. Alternatively, step 62 may comprise one or more diagnostic techniques. For some applications, the identification of the subject as having PAOD is performed using infrared emission information, e.g., based on infrared emission from a limb of the subject. For example, thermographic imaging or an infrared thermometer may be used. For some applications, the identification of the subject as having PAOD is performed by measuring the temperature of a limb of the subject using contact-based techniques. For some applications, the identification of the subject as having PAOD is performed using Doppler information that is indicative of blood flow in a limb of the subject. For some applications, ultrasound or laser technologies may be used to identify PAOD. For some applications, transcutaneous oximetry is used to identify the subject as having PAOD.
In response to the identification of the subject as having PAOD, an electrostimulator implant (e.g., implant 22) is percutaneously delivered into (e.g., implanted in) a limb of the subject (step 66).
The implant is activated such that the implant applies an electrical current to the limb. The step of activating the implant is not shown in the flowchart of
Circuitry 26 (e.g., control unit 28) of implant 22 is typically configured to configure the treatment current to have a frequency of below 100 Hz (e.g., 1-100 Hz). For example, the treatment current may have a frequency of 1-10 Hz (e.g., 2-5 Hz), 7-12 Hz (e.g., 10 Hz), 15-25 Hz (e.g., 20 Hz), or 35-45 Hz (e.g., 40 Hz). It has been observed by the inventors that a current having such a frequency is capable of increasing blood flow in the subject, e.g., in the limb in which the implant is implanted. Therefore the treatment current is also referred to herein as a bloodflow-increasing current.
Typically, the implant is implanted within a leg of the subject. Further typically, the implant is typically implanted within 10 mm (e.g., within 5 mm, such as within 2 mm) of a tibial nerve of the subject, such that, when activated, the implant applies the treatment current to the tibial nerve.
For some applications, percutaneous electrodes are temporarily introduced into the subject in order to identify an implantation site for implant 22 (e.g., prior to, or as part of, step 66). For some such applications, this is performed using, mutatis mutandis, techniques described in PCT application publication WO 2014/087337 to Gross et al (e.g., with reference to
For some applications, the implant may be repositioned or calibrated in response to changes in the subject caused by the implant (box 70). For example, at least in part responsively to a blood-flow change, implant 22 may be repositioned (step 72) or calibrated (step 74). Alternatively (e.g., for a subject that suffers from polyneuropathy in addition to PAOD) implant 22 may be configured to relieve pain (e.g., as described hereinbelow) as well as to increase blood flow, and at least in part responsively to a level of pain relief and/or of paresthesia, the implant may be repositioned (step 76) or calibrated (step 78). For some applications, both (i) a blood-flow change and (ii) a level of pain relief and/or paresthesia are identified, and the implant is repositioned and/or calibrated at least in part responsively to both (i) the blood-flow change and (ii) the level of pain relief and/or paresthesia. Blood-flow change may be detected using the same, or a different, technique to the technique used to identify the subject as having PAOD. For example, blood-flow change may be detected using one or more of the factors described hereinbelow with reference to
For some applications, implant 22 is configured to relieve pain by inducing paresthesia. For some applications, implant 22 is configured to relieve pain via high-frequency nerve blocking.
Steps 72, 74, 76 and 78 are contained within box 70, with no arrows therebetween, so as to illustrate that these steps may be performed in any order, and may be repeated, as necessary. For some applications,
Calibration of implant 22 typically comprises changing an characteristic of the treatment current, such as amplitude, frequency and/or pulse width. Calibration is typically performed wirelessly. Repositioning of implant 22 is typically performed before the implant has been fully deployed (e.g., fully released from introducer 40). For some applications, implant 22 is repositioned using, mutatis mutandis, techniques described in PCT application publication WO 2014/087337 to Gross et al. (e.g., with reference to FIGS. 1A-3 thereof), which is incorporated herein by reference in its entirety.
For some applications, the implant is implanted in a subject that does not suffer from peripheral polyneuropathy (e.g., does not suffer from pain caused by polyneuropathy). That is, for some applications, identifying the subject comprises also identifying that the subject does not suffer from peripheral polyneuropathy (step 64).
Reference is made to
Circuitry 86 (e.g., a control unit 88 thereof) of implant 82 is configured to alternate the implant between a first mode in which the implant applies a first current, and a second mode in which the implant applies a second current that differs in at least one characteristic (such as, but not limited to, frequency, amplitude, or pulse width) from the first current. Box 84 schematically illustrates this alternating between the first and second modes. The first current is the bloodflow-increasing current described hereinabove, and the second current is configured to induce pain relief. For some applications, the implant is calibrated to adjust one or both of the currents for the particular subject. For some applications, implant 82 remains in the first mode for a duration of 1-30 min (e.g., 2-20 min, such as 5-15 min). For some applications, implant 82 remains in the second mode for a duration of 1-30 min (e.g., 2-20 min, such as 5-15 min). The duration of the first mode may be the same as, or different from, the duration of the second mode.
As described hereinabove, the bloodflow-increasing first current has a frequency of 1-100 Hz. For applications in which pain relief is provided by inducing paresthesia, the second current may also have a frequency of 1-100 Hz. For applications in which pain relief is provided by high frequency nerve blocking, the second current typically has a frequency of 1-10 kHz.
Reference is made to
For some applications, one of sensors 104 and 110 is a temperature sensor, configured to detect temperature of the tissue in which the implant is implanted. For such applications, circuitry 106 (e.g., a control unit 108 thereof) of implant 102 is configured to drive electrodes 24 to apply the bloodflow-increasing current to the tissue at least in part responsively to the detected temperature, typically if the detected temperature drops below a threshold temperature, the drop in temperature being indicative of reduced blood flow in the limb.
For some applications, one of sensors 104 and 110 is configured to detect an oxygen saturation in the tissue in which the implant is disposed. For example, the sensor may be an oximeter. For such applications, circuitry 106 (e.g., control unit 108) is configured to drive electrodes 24 to apply the blood-flow increasing current at least in part responsively to the detected oxygen saturation. For example, at least in part responsively to the detected oxygen saturation being indicative of reduced blood flow in the limb (e.g., being lower than a threshold saturation), circuitry 106 (e.g., control unit 108) drives electrodes 24 to apply the bloodflow-increasing current.
For some applications, one of sensors 104 and 110 is a pressure sensor, configured to detect a blood pressure factor. For such applications, circuitry 106 (e.g., control unit 108) is configured to drive electrodes 24 to apply the blood-flow increasing current at least in part responsively to the detected blood pressure factor. For some such applications, the detected blood pressure factor comprises pulse pressure, and circuitry 106 (e.g., control unit 108) is configured to drive electrodes 24 to apply the bloodflow-increasing current at least in part responsively to the detected pulse pressure. For example, at least in part responsively to the detected blood pressure factor (e.g., pulse pressure) being indicative of reduced blood flow in the limb, circuitry 106 (e.g., control unit 108) drives electrodes 24 to apply the bloodflow-increasing current.
For some applications, one of sensors 104 and 110 is an accelerometer, configured to detect movement of the implant caused by expansion of an artery of the limb in which the implant is disposed. For such applications, circuitry 106 (e.g., control unit 108) is configured to drive electrodes 24 to apply the blood-flow increasing current at least in part responsively to the detected movement. For example, at least in part responsively to the detected movement being indicative of reduced blood flow in the limb, circuitry 106 (e.g., control unit 108) drives electrodes 24 to apply the bloodflow-increasing current. For such applications, circuitry 106 (e.g., control unit 108 thereof) is configured to distinguish movement of the implant caused by expansion of an artery, from movement of the implant caused by movement of the limb.
It is to be noted that implant 102 may comprise one or more of the above-described sensors, and circuitry 106 (e.g., control unit 108) may be configured to drive electrodes 24 to apply the blood-flow increasing current at least in part responsively to any combination of the detected factors.
Reference is made to
Extracorporeal device 130 comprises a power source (e.g., a battery) 132, an antenna 134, and a controller 136 that uses power from source 132 to drive antenna 134 to transmit wireless power, which is received by antenna 32 of implant 122, as described hereinabove, mutatis mutandis. For some applications, device 130 is configured to wirelessly drive (e.g., via circuitry of implant 122) one or more of the sensors (e.g., sensor 104 or sensor 110) of implant 122, and to receive from the implant information regarding the detected factor(s). At least in part responsively to this received information, controller 136 drives antenna 134 to wirelessly drive circuitry 106 (e.g., control unit 108 thereof) to drive electrodes 24 to apply the bloodflow-increasing current. That is, system 120 has similar overall functionality to implant 102, but with at least part of the information processing performed by extracorporeal device 130 rather than by the implant, thereby facilitating miniaturization of implant 122.
It is to be noted that antenna 134 may extend around part, most, or all of strap 131, so as to facilitate communication with implant 122.
For some applications, extracorporeal device 130 comprises at least one extracorporeal sensor, such as an extracorporeal sensor 138 and/or an extracorporeal sensor 140. Sensor 138 is an example of a sensor that is positioned to face the skin of the subject (e.g., to be placed in contact with the skin) when device 130 is attached to the limb, and sensor 140 is an example of a sensor that is typically positioned to face away from the skin of the subject when device 130 is attached to the limb. Typically, sensor 138 is configured to detect a factor indicative of local blood supply, and sensor 140 is configured to detect a factor of the environment. For example, for some applications, sensor 138 is an extracorporeal temperature sensor configured to detect a temperature of the limb, and sensor 140 is an extracorporeal temperature sensor configured to detect an ambient temperature. For such applications, controller 136 is configured to receive information regarding the temperature detected by at least one of the extracorporeal temperature sensors, and device 130 is configured to wirelessly drive circuitry 106 (e.g., control unit 108) of implant 122 to drive electrodes 24 to apply the bloodflow-increasing current to the tissue, at least in part responsively to the temperature detected by the at least one extracorporeal temperature sensor.
Alternatively or additionally, one or more of the extracorporeal sensors may be an oximeter, a pressure sensor, and/or an accelerometer, e.g., as described hereinabove for sensors 104 and 110, mutatis mutandis.
For some applications, the bloodflow-increasing current is driven in response to both (i) information received from the intracorporeal sensors of implant 122, and (ii) information received from the extracorporeal sensors of device 130.
For some applications, extracorporeal device 130 (e.g., controller 136 thereof) is configured to drive implant 122 to alternate between the first and second modes described with reference to
Reference is again made to
Reference is again made to
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3411507 | Wingrove | Nov 1968 | A |
| 3693625 | Auphan | Sep 1972 | A |
| 4019518 | Maurer et al. | Apr 1977 | A |
| 4338945 | Kosugi et al. | Jul 1982 | A |
| 4392496 | Stanton | Jul 1983 | A |
| 4535785 | van den Honert et al. | Aug 1985 | A |
| 4559948 | Liss et al. | Dec 1985 | A |
| 4573481 | Bullara | Mar 1986 | A |
| 4585005 | Lue et al. | Apr 1986 | A |
| 4602624 | Naples et al. | Jul 1986 | A |
| 4608985 | Crish et al. | Sep 1986 | A |
| 4628942 | Sweeney et al. | Dec 1986 | A |
| 4632116 | Rosen et al. | Dec 1986 | A |
| 4649936 | Ungar et al. | Mar 1987 | A |
| 4663102 | Brenman et al. | May 1987 | A |
| 4739764 | Lue et al. | Apr 1988 | A |
| 4808157 | Coombs | Feb 1989 | A |
| 4867164 | Zabara | Sep 1989 | A |
| 4926865 | Oman | May 1990 | A |
| 4962751 | Krauter | Oct 1990 | A |
| 5025807 | Zabara | Jun 1991 | A |
| 5069680 | Grandjean | Dec 1991 | A |
| 5178161 | Kovacs | Jan 1993 | A |
| 5188104 | Wernicke et al. | Feb 1993 | A |
| 5199428 | Obel et al. | Apr 1993 | A |
| 5199430 | Fang et al. | Apr 1993 | A |
| 5203326 | Collins | Apr 1993 | A |
| 5205285 | Baker, Jr. | Apr 1993 | A |
| 5215086 | Terry, Jr. et al. | Jun 1993 | A |
| 5263480 | Wernicke et al. | Nov 1993 | A |
| 5282468 | Klepinski | Feb 1994 | A |
| 5284479 | De Jong | Feb 1994 | A |
| 5292344 | Douglas | Mar 1994 | A |
| 5299569 | Wernicke et al. | Apr 1994 | A |
| 5314495 | Kovacs | May 1994 | A |
| 5330507 | Schwartz | Jul 1994 | A |
| 5335657 | Terry, Jr. et al. | Aug 1994 | A |
| 5411535 | Fujii et al. | May 1995 | A |
| 5423872 | Cigaina | Jun 1995 | A |
| 5439938 | Snyder et al. | Aug 1995 | A |
| 5454840 | Krakovsky et al. | Oct 1995 | A |
| 5487760 | Villafana | Jan 1996 | A |
| 5505201 | Grill, Jr. et al. | Apr 1996 | A |
| 5540730 | Terry, Jr. et al. | Jul 1996 | A |
| 5540733 | Testerman et al. | Jul 1996 | A |
| 5540734 | Zabara | Jul 1996 | A |
| 5549655 | Erickson | Aug 1996 | A |
| 5571150 | Wernicke et al. | Nov 1996 | A |
| 5591216 | Testerman et al. | Jan 1997 | A |
| 5634462 | Tyler et al. | Jun 1997 | A |
| 5690681 | Geddes et al. | Nov 1997 | A |
| 5690691 | Chen et al. | Nov 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5711316 | Elsberry et al. | Jan 1998 | A |
| 5716385 | Mittal et al. | Feb 1998 | A |
| 5755750 | Petruska et al. | May 1998 | A |
| 5776170 | Macdonald et al. | Jul 1998 | A |
| 5776171 | Peckham et al. | Jul 1998 | A |
| 5814089 | Stokes et al. | Sep 1998 | A |
| 5824027 | Hoffer et al. | Oct 1998 | A |
| 5832932 | Elsberry et al. | Nov 1998 | A |
| 5833709 | Rise et al. | Nov 1998 | A |
| 5836994 | Bourgeois | Nov 1998 | A |
| 5916239 | Geddes et al. | Jun 1999 | A |
| 5938584 | Ardito et al. | Aug 1999 | A |
| 5944680 | Christopherson et al. | Aug 1999 | A |
| 5954758 | Peckham et al. | Sep 1999 | A |
| 5991664 | Seligman | Nov 1999 | A |
| 6002964 | Feler et al. | Dec 1999 | A |
| 6026326 | Bardy | Feb 2000 | A |
| 6026328 | Peckham et al. | Feb 2000 | A |
| 6032076 | Melvin et al. | Feb 2000 | A |
| 6058331 | King | May 2000 | A |
| 6066163 | John | May 2000 | A |
| 6083249 | Familoni | Jul 2000 | A |
| 6086525 | Davey et al. | Jul 2000 | A |
| 6091977 | Tarjan et al. | Jul 2000 | A |
| 6091992 | Bourgeois et al. | Jul 2000 | A |
| 6094598 | Elsberry et al. | Jul 2000 | A |
| 6097984 | Douglas | Aug 2000 | A |
| 6104955 | Bourgeois | Aug 2000 | A |
| 6104960 | Duysens et al. | Aug 2000 | A |
| 6119516 | Hock | Sep 2000 | A |
| 6146335 | Gozani | Nov 2000 | A |
| 6148232 | Avrahami | Nov 2000 | A |
| 6161048 | Sluijter et al. | Dec 2000 | A |
| 6169924 | Meloy et al. | Jan 2001 | B1 |
| 6205359 | Boveja | Mar 2001 | B1 |
| 6212435 | Lattner et al. | Apr 2001 | B1 |
| 6214032 | Loeb et al. | Apr 2001 | B1 |
| 6230061 | Hartung | May 2001 | B1 |
| 6240316 | Richmond et al. | May 2001 | B1 |
| 6246912 | Sluijter et al. | Jun 2001 | B1 |
| 6266564 | Hill et al. | Jul 2001 | B1 |
| 6272383 | Grey et al. | Aug 2001 | B1 |
| 6292703 | Meier et al. | Sep 2001 | B1 |
| 6319241 | King et al. | Nov 2001 | B1 |
| 6332089 | Acker et al. | Dec 2001 | B1 |
| 6341236 | Osorio et al. | Jan 2002 | B1 |
| 6345202 | Richmond et al. | Feb 2002 | B2 |
| 6356784 | Lozano et al. | Mar 2002 | B1 |
| 6356788 | Boveja | Mar 2002 | B2 |
| 6366813 | DiLorenzo | Apr 2002 | B1 |
| 6405079 | Ansarinia | Jun 2002 | B1 |
| 6442432 | Lee | Aug 2002 | B2 |
| 6445953 | Bulkes et al. | Sep 2002 | B1 |
| 6449507 | Hill et al. | Sep 2002 | B1 |
| 6456878 | Yerich et al. | Sep 2002 | B1 |
| 6463328 | John | Oct 2002 | B1 |
| 6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
| 6496729 | Thompson | Dec 2002 | B2 |
| 6496730 | Kleckner et al. | Dec 2002 | B1 |
| 6600954 | Cohen et al. | Jul 2003 | B2 |
| 6600956 | Maschino et al. | Jul 2003 | B2 |
| 6606521 | Paspa et al. | Aug 2003 | B2 |
| 6610713 | Tracey | Aug 2003 | B2 |
| 6618627 | Lattner et al. | Sep 2003 | B2 |
| 6641542 | Cho et al. | Nov 2003 | B2 |
| 6735474 | Loeb et al. | May 2004 | B1 |
| 6770022 | Mechlenburg et al. | Aug 2004 | B2 |
| 6829508 | Schulman et al. | Dec 2004 | B2 |
| 6839594 | Cohen et al. | Jan 2005 | B2 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6909917 | Woods et al. | Jun 2005 | B2 |
| 7025730 | Cho et al. | Apr 2006 | B2 |
| 7027860 | Bruninga et al. | Apr 2006 | B2 |
| 7047076 | Li et al. | May 2006 | B1 |
| 7054692 | Whitehurst et al. | May 2006 | B1 |
| 7149575 | Ostroff et al. | Dec 2006 | B2 |
| 7177698 | Klosterman et al. | Feb 2007 | B2 |
| 7212867 | Van Venrooji et al. | May 2007 | B2 |
| 7228178 | Carroll et al. | Jun 2007 | B2 |
| 7277749 | Gordon et al. | Oct 2007 | B2 |
| 7289853 | Campbell et al. | Oct 2007 | B1 |
| 7324852 | Barolat et al. | Jan 2008 | B2 |
| 7324853 | Ayal et al. | Jan 2008 | B2 |
| 7389145 | Kilgore et al. | Jun 2008 | B2 |
| 7483752 | Von Arx et al. | Jan 2009 | B2 |
| 7532932 | Denker et al. | May 2009 | B2 |
| 7536226 | Williams et al. | May 2009 | B2 |
| 7628750 | Cohen et al. | Dec 2009 | B2 |
| 7630771 | Cauller | Dec 2009 | B2 |
| 7634313 | Kroll et al. | Dec 2009 | B1 |
| 7655014 | Ko et al. | Feb 2010 | B2 |
| 7657311 | Bardy et al. | Feb 2010 | B2 |
| 7657322 | Bardy et al. | Feb 2010 | B2 |
| 7660632 | Kirby et al. | Feb 2010 | B2 |
| 7680538 | Durand et al. | Mar 2010 | B2 |
| 7711434 | Denker et al. | May 2010 | B2 |
| 7736379 | Ewers et al. | Jun 2010 | B2 |
| 7780625 | Bardy | Aug 2010 | B2 |
| 7797050 | Libbus et al. | Sep 2010 | B2 |
| 7848818 | Barolat et al. | Dec 2010 | B2 |
| 7917226 | Nghiem et al. | Mar 2011 | B2 |
| 7937148 | Jacobson | May 2011 | B2 |
| 7941218 | Sambelashvili et al. | May 2011 | B2 |
| 7974706 | Moffitt et al. | Jul 2011 | B2 |
| 7991467 | Markowitz et al. | Aug 2011 | B2 |
| 7996089 | Haugland et al. | Aug 2011 | B2 |
| 7996092 | Mrva et al. | Aug 2011 | B2 |
| 8019443 | Schleicher et al. | Sep 2011 | B2 |
| 8055350 | Roberts | Nov 2011 | B2 |
| 8075556 | Betts | Dec 2011 | B2 |
| 8090438 | Bardy et al. | Jan 2012 | B2 |
| 8131377 | Shi et al. | Mar 2012 | B2 |
| 8170675 | Alataris et al. | May 2012 | B2 |
| 8177792 | Lubock et al. | May 2012 | B2 |
| 8185207 | Molnar et al. | May 2012 | B2 |
| 8209021 | Alataris et al. | Jun 2012 | B2 |
| 8224453 | De Ridder | Jul 2012 | B2 |
| 8255057 | Fang et al. | Aug 2012 | B2 |
| 8355792 | Alataris et al. | Jan 2013 | B2 |
| 8359102 | Alataris et al. | Jan 2013 | B2 |
| 8359103 | Alataris et al. | Jan 2013 | B2 |
| 8396559 | Alataris et al. | Mar 2013 | B2 |
| 8428748 | Alataris et al. | Apr 2013 | B2 |
| 8509905 | Alataris et al. | Aug 2013 | B2 |
| 8509906 | Walker et al. | Aug 2013 | B2 |
| 8554326 | Alataris et al. | Oct 2013 | B2 |
| 8634927 | Olson et al. | Jan 2014 | B2 |
| 8649874 | Alataris et al. | Feb 2014 | B2 |
| 8694108 | Alataris et al. | Apr 2014 | B2 |
| 8694109 | Alataris et al. | Apr 2014 | B2 |
| 8712533 | Alataris et al. | Apr 2014 | B2 |
| 8718781 | Alataris et al. | May 2014 | B2 |
| 8718782 | Alataris et al. | May 2014 | B2 |
| 8755893 | Gross et al. | Jun 2014 | B2 |
| 8768472 | Fang et al. | Jul 2014 | B2 |
| 8774926 | Alataris et al. | Jul 2014 | B2 |
| 8788045 | Gross et al. | Jul 2014 | B2 |
| 8792988 | Alataris et al. | Jul 2014 | B2 |
| 8849410 | Walker et al. | Sep 2014 | B2 |
| 8862239 | Alataris et al. | Oct 2014 | B2 |
| 8868192 | Alataris et al. | Oct 2014 | B2 |
| 8874217 | Alataris et al. | Oct 2014 | B2 |
| 8874221 | Alataris et al. | Oct 2014 | B2 |
| 8874222 | Alataris et al. | Oct 2014 | B2 |
| 8880177 | Alataris et al. | Nov 2014 | B2 |
| 8886326 | Alataris et al. | Nov 2014 | B2 |
| 8886327 | Alataris et al. | Nov 2014 | B2 |
| 8886328 | Alataris et al. | Nov 2014 | B2 |
| 8892209 | Alataris et al. | Nov 2014 | B2 |
| 20020077554 | Schwartz et al. | Jun 2002 | A1 |
| 20020099419 | Cohen et al. | Jul 2002 | A1 |
| 20020124848 | Sullivan et al. | Sep 2002 | A1 |
| 20020183805 | Fang et al. | Dec 2002 | A1 |
| 20020183817 | Van Venrooij et al. | Dec 2002 | A1 |
| 20030040774 | Terry, Jr. et al. | Feb 2003 | A1 |
| 20030060858 | Kieval et al. | Mar 2003 | A1 |
| 20030100933 | Ayal et al. | May 2003 | A1 |
| 20030114905 | Kuzma | Jun 2003 | A1 |
| 20030176898 | Gross et al. | Sep 2003 | A1 |
| 20040015205 | Whitehurst et al. | Jan 2004 | A1 |
| 20040019368 | Lattner et al. | Jan 2004 | A1 |
| 20040048795 | Ivanova et al. | Mar 2004 | A1 |
| 20040073270 | Firlik et al. | Apr 2004 | A1 |
| 20040167584 | Carroll et al. | Aug 2004 | A1 |
| 20040249431 | Ransbury et al. | Dec 2004 | A1 |
| 20040254612 | Ezra et al. | Dec 2004 | A1 |
| 20040254624 | Johnson | Dec 2004 | A1 |
| 20050113894 | Zilberman et al. | May 2005 | A1 |
| 20050131495 | Parramon et al. | Jun 2005 | A1 |
| 20050143789 | Whitehurst et al. | Jun 2005 | A1 |
| 20050165457 | Benser et al. | Jul 2005 | A1 |
| 20060085039 | Hastings et al. | Apr 2006 | A1 |
| 20060100668 | Ben-David et al. | May 2006 | A1 |
| 20060155345 | Williams et al. | Jul 2006 | A1 |
| 20060271137 | Stanton-Hicks | Nov 2006 | A1 |
| 20070032827 | Katims | Feb 2007 | A1 |
| 20070067000 | Strother et al. | Mar 2007 | A1 |
| 20070067007 | Schulman et al. | Mar 2007 | A1 |
| 20070073354 | Knudson et al. | Mar 2007 | A1 |
| 20070083240 | Peterson et al. | Apr 2007 | A1 |
| 20070173893 | Pitts | Jul 2007 | A1 |
| 20070208392 | Kuschner et al. | Sep 2007 | A1 |
| 20070255369 | Bonde et al. | Nov 2007 | A1 |
| 20070293912 | Cowan et al. | Dec 2007 | A1 |
| 20080009914 | Buysman et al. | Jan 2008 | A1 |
| 20080021336 | Dobak | Jan 2008 | A1 |
| 20080027513 | Carbunaru | Jan 2008 | A1 |
| 20080039915 | Van Den Biggelaar et al. | Feb 2008 | A1 |
| 20080103407 | Bolea et al. | May 2008 | A1 |
| 20080103572 | Gerber | May 2008 | A1 |
| 20080119911 | Rosero | May 2008 | A1 |
| 20080132964 | Cohen et al. | Jun 2008 | A1 |
| 20080269740 | Bonde et al. | Oct 2008 | A1 |
| 20090012590 | Inman et al. | Jan 2009 | A1 |
| 20090036975 | Ward et al. | Feb 2009 | A1 |
| 20090048642 | Goroszeniuk | Feb 2009 | A1 |
| 20090149912 | Dacey et al. | Jun 2009 | A1 |
| 20090152954 | Le et al. | Jun 2009 | A1 |
| 20090204170 | Hastings et al. | Aug 2009 | A1 |
| 20090204173 | Fang et al. | Aug 2009 | A1 |
| 20090270951 | Kallmyer | Oct 2009 | A1 |
| 20090281594 | King et al. | Nov 2009 | A1 |
| 20090326602 | Glukhovsky | Dec 2009 | A1 |
| 20100016911 | Willis et al. | Jan 2010 | A1 |
| 20100094367 | Sen | Apr 2010 | A1 |
| 20100121405 | Ternes et al. | May 2010 | A1 |
| 20100125310 | Wilson et al. | May 2010 | A1 |
| 20100125313 | Lee et al. | May 2010 | A1 |
| 20100198298 | Glukhovsky et al. | Aug 2010 | A1 |
| 20100211131 | Williams et al. | Aug 2010 | A1 |
| 20100241195 | Meadows et al. | Sep 2010 | A1 |
| 20100249875 | Kishawi et al. | Sep 2010 | A1 |
| 20100305392 | Gross et al. | Dec 2010 | A1 |
| 20100312320 | Faltys et al. | Dec 2010 | A1 |
| 20100324630 | Lee et al. | Dec 2010 | A1 |
| 20110034782 | Sugimachi | Feb 2011 | A1 |
| 20110046696 | Barolat et al. | Feb 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110093036 | Mashiach | Apr 2011 | A1 |
| 20110137365 | Ben-Ezra et al. | Jun 2011 | A1 |
| 20110152965 | Mashiach et al. | Jun 2011 | A1 |
| 20110160792 | Fishel | Jun 2011 | A1 |
| 20110160793 | Gindele | Jun 2011 | A1 |
| 20110160798 | Ackermann, Jr. et al. | Jun 2011 | A1 |
| 20110208260 | Jacobson | Aug 2011 | A1 |
| 20110208271 | Dobak | Aug 2011 | A1 |
| 20110224744 | Moffitt et al. | Sep 2011 | A1 |
| 20110230922 | Fishel | Sep 2011 | A1 |
| 20110251660 | Griswold | Oct 2011 | A1 |
| 20110270339 | Murray, III et al. | Nov 2011 | A1 |
| 20110282412 | Glukhovsky et al. | Nov 2011 | A1 |
| 20110301670 | Gross et al. | Dec 2011 | A1 |
| 20120035679 | Dagan et al. | Feb 2012 | A1 |
| 20120041511 | Lee | Feb 2012 | A1 |
| 20120041514 | Gross et al. | Feb 2012 | A1 |
| 20120065701 | Cauller | Mar 2012 | A1 |
| 20120083857 | Bradley et al. | Apr 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120123498 | Gross | May 2012 | A1 |
| 20120130448 | Woods et al. | May 2012 | A1 |
| 20120130463 | Ben-David et al. | May 2012 | A1 |
| 20120158081 | Gross et al. | Jun 2012 | A1 |
| 20120296389 | Fang et al. | Nov 2012 | A1 |
| 20130006326 | Ackermann et al. | Jan 2013 | A1 |
| 20130066393 | Gross et al. | Mar 2013 | A1 |
| 20130325081 | Karst et al. | Dec 2013 | A1 |
| 20140214134 | Peterson | Jul 2014 | A1 |
| 20140296940 | Gross | Oct 2014 | A1 |
| 20150004709 | Nazarpoor | Jan 2015 | A1 |
| 20150018728 | Gross | Jan 2015 | A1 |
| 20150080979 | Lasko et al. | Mar 2015 | A1 |
| 20150100109 | Feldman et al. | Apr 2015 | A1 |
| 20150258339 | Burchiel | Sep 2015 | A1 |
| 20150335882 | Gross et al. | Nov 2015 | A1 |
| 20170119435 | Gross et al. | May 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 102008054403 | Jun 2010 | DE |
| 0688577 | Dec 1995 | EP |
| 1533000 | May 2005 | EP |
| 9810832 | Mar 1998 | WO |
| WO9926530 | Jun 1999 | WO |
| WO 0110375 | Feb 2001 | WO |
| WO 0110432 | Feb 2001 | WO |
| WO 0126729 | Apr 2001 | WO |
| WO0209808 | Feb 2002 | WO |
| 2004064729 | Aug 2004 | WO |
| 2006102626 | Sep 2006 | WO |
| 2007019491 | Feb 2007 | WO |
| 2009055574 | Apr 2009 | WO |
| WO 2009110935 | Sep 2009 | WO |
| WO 2011154937 | Dec 2011 | WO |
| 2012012591 | Jan 2012 | WO |
| 2013106884 | Jul 2013 | WO |
| WO 2013111137 | Aug 2013 | WO |
| 2013156038 | Oct 2013 | WO |
| 2014068577 | May 2014 | WO |
| 2014068577 | May 2014 | WO |
| WO2014081978 | May 2014 | WO |
| WO 2014087337 | Jun 2014 | WO |
| WO2014167568 | Oct 2014 | WO |
| WO2015004673 | Jan 2015 | WO |
| 2016172109 | Oct 2016 | WO |
| Entry |
|---|
| Brindley (1983) A technique for anodally blocking large nerve fibers. |
| DJOGlobal.com—Interferential Current Therapy (IFC), Accessed Mar. 19, 2015. |
| U.S. Appl. No. 60/985,353, filed Nov. 5, 2007. |
| electrotherapy.org—Interferential Therapy, Accessed Mar. 19, 2015. |
| Lind (2012) Advances in spinal cord stimulation. |
| Physical Therapy Web.com—Interferential Current (IFC) Equipment, Accessed Mar. 19, 2015. |
| Shealy (1967) Electrical inhibition of pain by stimulation of the dorsal columns. |
| Nov. 30, 2015 massdevice.com—St. Jude Medical's Proclaim Elite debuts in Europe. |
| Kaplan et al. (2009) Design and fabrication of an injection tool for neuromuscular microstimulators. |
| Supplementary European Search Report dated Dec. 22, 2014, which issued during the prosecution of Applicant's European App No. 11792044.7. |
| An Office Action dated Oct. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/226,723. |
| Reggiani (2009) Biophysical effects of high frequency electrical field on muscle fibers in culture. |
| Jimmie Hagblad (2011) Non-Invasive Techniques for Assessment of Peripheral Blood Flow at Different Vascular Depths. |
| Office Action received in U.S. Appl. No. 13/528,433 dated Dec. 5, 2013. |
| C. Seper, “Neuros Medical Launches to Develop New Device to Block Amputee, Chronic Pain,” Mar. 2009, 6 pages. |
| Urgent PC, Simple. Safe. Effective. Neuromodulation System, Uroplasty Mar. 2009, 3 pages. |
| “JumpStart and Case Technology Ventures Invest in Neuros Medical,” CTV Case Technology Ventures Mar. 2009, 3 pages. |
| P.J. Theuvent, et al., “Responses to Median and Tibial Nerve Stimulation in Patients with Chronic Neuropathic Pain,” Brain Topography, 1999, pp. 305-313, vol. 11, No. 4, an Abstract, 1 page. |
| J Armstrong et al., “Is Electrical Stimulation Effective in Reducing Neuropathic Pain in Patients with Diabetes,” Foot Ankle Surg., Jul.-Aug. 1997, vol. 36, No. 4, an Abstract, 1 page. |
| C. de Balthasar, G. Cosendai, M. Hansen, D. Canfield, L. Chu, R. Davis, and J. Schulman, “Attachment of leads to RFBIONO microstimulators.” Jul. 2005. |
| D.W. Eisele, A.R. Schwartz, and P.L. Smith, “Tongue neuromuscular and direct hypoglossal nerve stimulation for obstructive sleep apnea.,” Otolaryngologic clinics of North America, vol. 36, 2003, p. 501. |
| G.E. Loeb, F.J.R. Richmond, J. Singh, R.A. Peck, W. Tan, Q. Zou, and N. Sachs, “RF-powered BIONsTM for stimulation and sensing,” Engineering in Medicine and Biology Society, 2004. IEMBST04. 26th Annual International Conference of the IEEE, 2005, pp. 4182-4185. |
| G“E Loeb, ” F J Richmond, and L.L. Baker, “The BION devices: injectable interfaces with peripheral nerves and muscles,” Neurosurgical focus, vol. 20, 2006, pp. 1-9. |
| E.A. A Mann, T. T Burnett, S. Cornell, and C.L. Ludlow, “The effect of neuromuscular stimulation of the genioglossus on the hypopharyngeal airway,” The Laryngoscope, vol. 112, 2002, pp. 351-356. |
| A. Oliven, R.P. Schnall, G. Pillar, N. Gavriely, and M. Odeh, “Sublingual electrical stimulation of the tongue during wakefulness and sleep,” Respiration physiology, vol. 127, 2001, pp. 217-226. |
| A. Oliven, D.J. O'Hearn, A. Boudewyns, M. Odeh, W. De Backer, P. van de Heyning, P.L. Smith, D.W. Eisele, L. Allan, H. Schneider, and others, “Upper airway response to electrical stimulation of the genioglossus in obstructive sleep apnea,” Journal of Applied Physiology, vol. 95, 2003, p. 2023. |
| A. Oliven, M. Odeh, L. Geitini, R. Oliven, U. Steinfeld, A.R. Schwartz, and N. Toy, “Effect of coactivation of tongue protrusor and retractor muscles on pharyngeal lumen and airflow in sleep apnea patients,” Journal of Applied Physiology, vol. 103, 2007, p. 1662. |
| A.R. Schwartz, D.W. Eisele, A. Hari, R. Testerman, D. Erickson, and P.L. Smith, “Electrical stimulation of the lingual musculature in obstructive sleep apnea,” Journal of Applied Physiology, vol. 81, 1996, p. 643. |
| W.H. Tran, G.E. Loeb, F.J.R. Richmond, A.C. Dupont, K.C. Mahutte, C.S.H. Sassoon, and M.J. Dickel, “Development of asynchronous, intralingual electrical stimulation to treat obstructive sleep apnea,” Engineering in Medicine and Biology Society, 2003. Proceedings of the 25th Annual International Conference of the IEEE, 2004, pp. 375-378. |
| W.H. Tran, G.E. Loeb, F.J.R. Richmond, R. Ahmed, G.T. Clark, and P.B. Haberman, “First subject evaluated with simulated BION TM treatment in genioglossus to prevent obstructive sleep apnea,” Engineering in Medicine and Biology Society, 2004. IEMBS'04. 26th Annual International Conference of the IEEE, 2005, pp. 4287-4289. |
| P.R. Troyk, “Injectable electronic identification, monitoring, and stimulation systems,” Biomedical Engineering, vol. 1, 1999, p. 177. |
| T.K. K Whitehurst, J.H. H Schulman, K.N. Jaax, and R. Carbunaru, The Bion® Microstimulator and its Clinical ,, Applications, Implantable Neural Prostheses 1, 2009, pp. 253-273. |
| D″ J Young, “Wireless powering and data telemetry for biomedical implants,” Engineering in Medicine and Biology Society, 2009. EMBC 2009. Annual International Conference of the IEEE, 2009, pp. 3221-3224. |
| Reid R. Harrison, et al. “Wireless Neural Recording with Single Low-Power Integrated Circuit”, IEEE Trans Neural Syst Rehabil Eng, Aug. 2009; 17(4): 322-329. |
| An International Search Report and a Written Opinion both dated Apr. 17, 2012 which issued during the prosecution of PCT/IL11/00870. |
| Patents Galore: Implantable Neurostimulators Fight Snoring and Corpse Eye-Proof Scanners. Printout from http://niedgadget.com/2006/03/patents galore.htnril (Downloaded Jan. 2012). |
| Ross Davis, Cerebellar Stimulation for Cerebral Palsy Spasticity, Function and Seizures. Clinical Neuroscience Center, 1999. pp. 290-299. |
| Bathien et al., Inhibition and synchronisation of tremor induced by a muscle twitch. J. Neurol, Neurosurg. and Psych. 1980, 43, 713-718. |
| Jobges et al., Vibratory proprioceptive stimulation affects Parkinsonian tremor. Parkinsonism & Related Disorders, 8 (3), 171-176, Jan. 2002. |
| R.J. Mones, A.H. Weiss, The response of the tremor of patients with Parkinsonism to peripheral nerve stimulation. J. Neurol. Neurosurg. Psychiat. 1969, 32. 512-518. |
| Y. Zhang, et al. “Optimal Ventricular Rate Slowing During Atrial Fibrillation by Feedback AV Nodal-Selective Vagal Stimulation”, Am J Physiol Heart Circ Physiol 282:H1102-H1110, 2002. |
| M. Manfredi, “Differential Block of conduction of larger fibers in peripheral nerve by direct current”, Arch. Ital. Biol. 108:52-71, 1970. |
| B.S. Russman, MD., Cerebral Palsy, Current Science Inc. 2000. |
| An International Search Report and a Written Opinion both dated Nov. 14, 2011, which issued during the prosecution of Applicant's PCT/IL2011/000440. |
| An International Preliminary Report on Patentability dated Dec. 10, 2012, which issued during the prosecution of Applicant's PCT/IL2011/000440. |
| Sweeney JD et al., “An asymmetric two electrode cuff for generation of unidirectionally propagated action potentials,” IEEE Transactions on Biomedical Engineering, vol. BME-33(6) (1986). |
| Partial ISR dated May 10, 2013 which issued during the prosecution of Applicant's PCT/IL2013050069. |
| Baratta R et al., “Orderly stimulation of skeletal muscle motor units with tripolar nerve cuff electrode,” IEEE Transactions on Biomedical Engineering, 36(8):836-43 (1989). |
| G• G: Naples et al., “A spiral nerve cuff electrode for peripheral nerve stimulation,” by IEEE Transactions on Biomedical Engineering, 35(11) (1988). |
| Sweeney JD et al., “A nerve cuff technique for selective excitation of peripheral nerve trunk regions,” IEEE Transactions on Biomedical Engineering, 37(7) (1990). |
| Ungar IJ et al., “Generation of unidirectionally propagating action potentials using a monopolar electrode cuff,” Annals of Biomedical Engineering, 14:437-450 (1986). |
| Fitzpatrick et al., in “A nerve cuff design for the selective activation and blocking of myelinated nerve fibers,” Ann. Conf. of the IEEE Eng. in Medicine and Biology Sac, 13(2), 906 (1991). |
| Rijkhoff NJ et al., “Orderly recruitment of motoneurons in an acute rabbit model,” Ann. Conf. of the IEEE Eng., Medicine and Biology Soc., 20(5):2564 (1998). |
| Van den Honed C et al., “A technique for collision block of peripheral nerve: Frequency dependence,” MP-12, IEEE Trans. Biomed. Eng. 28:379-382 (1981). |
| An Office Action dated Dec. 12, 2016, which issued during the prosecution of U.S. Appl. No. 14/939,418. |
| An Office Action dated Nov. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/601,626. |
| An Office Action dated Dec. 5, 2013, which issued during the prosecution of U.S. Appl. No. 13/528,433. |
| An Office Action dated Sep. 30, 2013, which issued during the prosecution of U.S. Appl. No. 12/796,102. |
| A Notice of Allowance dated Mar. 7, 2005, which issued during the prosecution of U.S. Appl. No. 10/254,024. |
| A Notice of Allowance dated Aug. 26, 2004, which issued during the prosecution of U.S. Appl. No. 10/254,024. |
| An Office Action dated Feb. 13, 2004, which issued during the prosecution of U.S. Appl. No. 10/254,024. |
| A Restriction Requirement dated May 11, 2012, which issued during the prosecution of U.S. Appl. No. 12/946,246. |
| An Office Action dated Jun. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/796,102. |
| An Office Action dated Apr. 9, 2012, which issued during the prosecution of U.S. Appl. No. 12/796,102. |
| U.S. Appl. No. 60/263,834, filed Jan. 2, 2001. |
| Sinan Filiz, Luke Xie, Lee E. Weiss, O.B. Ozdoganlar, Micromilling of microbarbs for medical implants, International Journal of Machine Tools and Manufacture, vol. 48, Issues 3-4, Mar. 2008, pp. 459-472. |
| UCLA Team Reports Initial Success with Trigeminal Nerve Stimulation epilepsy. https://web.archive.org/web/20121020145122/https:/www.epilepsy.com/epilepsy/newsletter/apr09—STIM. |
| Szmurlo, R., Starzynski, J., Wincenciak, S. and Rysz, A. (2009) ‘Numerical model of vagus nerve electrical stimulation’, COMPEL—The international journal for computation and mathematics in electrical and electronic engineering, 28(1), pp. 211-220. |
| Kucklick, Theodore R., ed. The medical device R&D handbook. Chapter 3—Intro to needles and cannulae. CRC Press, 2012. |
| An Office Action dated Feb. 27, 2017, which issued during the prosecution of U.S. Appl. No. 14/649,873. |
| An Office Action dated Apr. 5, 2017, which issued during the prosecution of U.S. Appl. No. 14/374,375. |
| European Search Report dated Feb. 3, 2017, which issued during the prosecution of Applicant's European App No. 16196878.9. |
| An Office Action dated Apr. 4, 2017, which issued during the prosecution of U.S. Appl. No. 14/601,604. |
| European Search Report dated Mar. 10, 2017, which issued during the prosecution of Applicant's European App No. 16196864.9. |
| Number | Date | Country | |
|---|---|---|---|
| 20160361544 A1 | Dec 2016 | US |
